---
title: "Invivyd | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 13.74 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286405997.md"
datetime: "2026-05-14T11:14:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286405997.md)
  - [en](https://longbridge.com/en/news/286405997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286405997.md)
---

# Invivyd | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 13.74 M

Revenue: As of FY2026 Q1, the actual value is USD 13.74 M, missing the estimate of USD 18.05 M.

EPS: As of FY2026 Q1, the actual value is USD -0.13, missing the estimate of USD -0.0733.

EBIT: As of FY2026 Q1, the actual value is USD -44.87 M.

### Financial Performance

#### Net Product Revenue

Invivyd, Inc. reported PEMGARDA® net product revenue of $13.7 million for Q1 2026, which represents a 22% year-over-year growth compared to $11.3 million in Q1 2025 . Historical PEMGARDA® net product revenue included $0 in Q1 2024, $2.3 million in Q2 2024, $9.3 million in Q3 2024, and $13.8 million in Q4 2024 . For 2025, the revenue figures were $11.3 million in Q1, $11.8 million in Q2, $13.1 million in Q3, and $17.2 million in Q4 .

#### Operating Expenses

Operating expenses increased quarter-over-quarter, primarily due to costs associated with the DECLARATION pivotal program for VYD2311 .

#### Cash and Funding

As of March 2026, Invivyd, Inc. held $184.2 million in cash and cash equivalents . The company also secured an additional approximately $20 million in gross proceeds from an at-the-market (ATM) offering facility in April 2026 and raised over $200 million in the second half of 2025 .

### Operational Metrics

#### Commercial Reach and Engagement

Invivyd, Inc. has established a strong commercial foundation for PEMGARDA®, with approximately 1,000 accounts having infusion experience and about 1,850 available sites for infusion . There are approximately 19,500 GPO contracted sites, and 77% of accounts are reordering . The company observed a 300% increase in PEMGARDA® HCP queries in Oncology and a 140% increase in Infectious Diseases, indicating an increase in new brand engagement through an AI-powered platform .

### Outlook and Guidance

Invivyd, Inc. expects topline data for the VYD2311 DECLARATION pivotal study in Q3 2026 and plans to initiate a pediatric study for VYD2311 in Q2 2026 . The company is targeting IND readiness for VMS063 (measles antibody candidate) in late 2026 and advancing VBY329 (RSV antibody candidate) toward IND readiness in the second half of 2026 . Invivyd, Inc. is also building out its commercial organization in preparation for a potential VYD2311 launch, if approved, and plans a near-term launch of a Long COVID study, aiming to broaden its pipeline .

### Related Stocks

- [IVVD.US](https://longbridge.com/en/quote/IVVD.US.md)

## Related News & Research

- [Invivyd Q1 net loss per share misses on higher R&D costs](https://longbridge.com/en/news/286405768.md)
- [Auburn National Bancorporation declares $0.27 quarterly dividend payable June 25](https://longbridge.com/en/news/286281680.md)
- [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md)
- [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md)
- [HPE to Present Live Audio Webcast of Fiscal 2026 Second Quarter Earnings Conference Call | HPE Stock News](https://longbridge.com/en/news/285935495.md)